Vitamin D3 for Life

Live Enlightened

Physiology

Vitamin D, Cortisol and Glucocorticoid Responses: Full Study

Previous related pageVitamin D, Cortisol and Glucocorticoid Responses: Study SummaryNext related pageVitamin D, Cortisol and Glucocorticoid Responses: Study Summary
Study at a glance

What did studies examine about vitamin D, cortisol and fatigue?

This review compares human trials measuring cortisol, stress responses or fatigue with laboratory studies of immune cells. Cortisol is a hormone involved in the stress response. The cell studies tested calcitriol, the active vitamin D hormone, with dexamethasone, a drug used to examine responses to glucocorticoids, the group of hormones that includes cortisol. Cell responses and control of cortisol in a person are different questions.

Did vitamin D improve cortisol levels or recovery from stress?

A small trial in women with multiple sclerosis did not establish a reliable benefit for daily cortisol, fatigue or depressive symptoms. A finding about the cortisol response after waking became uncertain after allowing for starting differences. A separate winter trial in male forensic inpatients did not establish a cortisol benefit or a clear treatment difference in recovery from the stress task. Neither demonstrated restoration of the feedback signals that help control stress hormones.

Did vitamin D improve fatigue in a separate trial?

A separate four-week trial in otherwise healthy adults with fatigue and low vitamin D found greater improvement on its main fatigue scale with vitamin D than placebo. Another fatigue measure did not show a clear difference. The trial did not measure cortisol or the feedback signals that help control stress hormones, so it cannot explain the improvement through that mechanism or establish a lasting benefit.

Did active vitamin D change immune-cell responses to dexamethasone?

Active vitamin D strengthened selected responses that help control immune activity in one asthma-related immune-cell system, but reduced some responses to glucocorticoids in another. Cell type and the order in which treatments were given mattered. These findings do not show that vitamin D always makes cells more responsive to glucocorticoids. They also do not establish a supplement dose, treatment for chronic fatigue syndrome or a general improvement in the ability to cope with stress.

Read the full article below ↓

Vitamin D can alter glucocorticoid responses in particular human cell experiments, but the selected clinical trials do not establish that supplementation restores hypothalamic-pituitary-adrenal (HPA) axis feedback. Cortisol measurements, laboratory stress responses and self-reported fatigue tell different parts of this story. Reading them together reveals both plausible interactions and important gaps between a cellular mechanism and a demonstrated benefit for people. For the shorter account, see Vitamin D, Cortisol and Glucocorticoid Responses: Study Summary.

What an HPA-axis claim needs to demonstrate

The hypothalamic: pituitary: adrenal axis links central regulation with glucocorticoid output. In these studies, cortisol is the principal measured human hormone, while dexamethasone is used experimentally to probe responses to a glucocorticoid in cells. The wider physiology is introduced in Vitamin D and the HPA Axis. The central question here is narrower: which parts of that system were actually tested when investigators changed vitamin D exposure?

A daily cortisol profile describes concentrations across a sampling schedule. The cortisol awakening response describes the early period after waking. A laboratory challenge asks whether a particular task changes the measured response. A feedback challenge would ask a different question about the system’s response to a suppressing or stimulating intervention. These measurements cannot be exchanged simply because each concerns cortisol.

Cellular experiments add another distinction. A change in glucocorticoid receptor abundance, movement into the nucleus or downstream gene expression concerns the responsiveness of those cells under the experimental conditions. It does not directly measure the brain’s regulation of circulating cortisol. This review compares the studies at those separate levels rather than treating them as successive demonstrations of one established treatment mechanism.

This is an original VD3FL analysis of the five cited publications, not the original research report. The main papers and material figures were examined during the evidence review, together with the identified relevant supplements.

The multiple-sclerosis trial measured daily cortisol and awakening responses

Rolf and colleagues conducted a multicentre, double-blind, placebo-controlled trial in premenopausal women with relapsing-remitting multiple sclerosis. Participants received 4,000 IU of cholecalciferol daily or placebo for approximately 16 weeks, alongside their existing care. Participants with current major depression were excluded, and measurements were scheduled in a standardised phase of the menstrual cycle or pill-free interval. These choices reduced some hormonal variation but narrowed the population to which the findings apply.

The trial did not reach its originally planned recruitment. Of 54 randomised participants, 44 received the allocated intervention and 43 completed the study. Two participants who received glucocorticoids for relapses were excluded from the analysis, leaving 22 in the vitamin D group and 19 in the placebo group. Excluding an intervention that directly affects glucocorticoid biology is understandable, but the resulting comparison is small and contains post-randomisation exclusions.

Saliva was collected immediately after waking and every 15 minutes during the following hour, with additional samples later in the day. Sampling occurred on two consecutive days, and corresponding measurements were averaged. Cortisol was measured using liquid chromatography: tandem mass spectrometry. The design therefore provided more information than a single morning blood or saliva result, while still depending on adherence to the sampling schedule. Daily and awakening responses were summarised as areas under the sampled curves; the daily slope used log-transformed cortisol. Fatigue was assessed with the Fatigue Severity Scale and depressive symptoms with HADS-D, not with the fatigue instrument used in Nowak’s trial.

Vitamin D status clearly changed: the final median 25-hydroxyvitamin D concentration was approximately 139.9 nmol/L in the supplemented group and 74.5 nmol/L with placebo. Baseline concentrations were already around 85 and 78 nmol/L, respectively. This was consequently not a trial confined to severely deficient women. Successful separation of vitamin D status establishes that the intervention changed its biochemical exposure; it does not establish the hoped-for endocrine or symptom outcome. Functional Vitamin D Status: Biological Response Beyond Circulating Levels: Full Study develops the broader distinction between a circulating biomarker and downstream biological responses.

The adjusted awakening comparison limits the positive interpretation

Between-group changes in the daily cortisol measure and its slope were not statistically significant, with p values of .915 and .347. The awakening-response comparison was more suggestive: the unadjusted comparison of change gave p=.044, but the comparison accounting for baseline awakening response gave p=.066. The analysis also considered age and baseline vitamin D status, which did not contribute significantly to the reported model.

This distinction matters because the groups began with numerically different awakening responses. A change score and a baseline-adjusted follow-up comparison are not identical analyses. Selecting only the smaller p value would hide a material qualification. Conversely, p=.066 does not establish that the true effect is exactly zero. The appropriate conclusion is that this small trial did not establish a robust treatment effect on the measured cortisol outcomes.

The authors suggested the awakening response as a useful outcome for further investigation. That is a research proposal, not proof that HPA-axis suppression has been demonstrated or that suppression would improve multiple-sclerosis outcomes. No ACTH measurement, dexamethasone feedback test or receptor-level assay established the proposed sequence from supplementation to central feedback regulation.

Fatigue and depressive-symptom comparisons were also null: p=.946 for fatigue and p=.714 for depressive symptoms. Depression scores were low at entry, so this is not evidence about treatment of a population with major depression. The study illustrates a general interpretive point relevant to Vitamin D and Hormones: changing the status of one endocrine-related substance does not guarantee a measurable change in another hormone, a symptom or a clinical outcome.

The winter stress trial did not establish a cortisol or resilience benefit

Hansen and colleagues studied a different population: male forensic inpatients receiving 1,600 IU of vitamin D3 daily or placebo during winter. Eighty-six men were randomised and 78 completed the study, 39 per group. The post-intervention tests occurred after approximately three to four months. Baseline mean vitamin D concentrations were around 59 and 63 nmol/L, so this was again not a selected severe-deficiency trial.

Participants undertook cognitive tasks accompanied by aversive noise. Heart rate and high-frequency heart-rate variability were assessed during baseline, task and recovery periods. Salivary cortisol samples covered evening, awakening and task-related periods. These are complementary measurements within Vitamin D and Stress Physiology: autonomic activity and endocrine output can respond differently to the same procedure.

No significant supplementation effect was established for cortisol or serotonin. Moreover, the experimental task did not produce a significant pooled cortisol rise. A procedure that changes heart rate can still be a weak test of cortisol reactivity in a particular sample. The absence of a cortisol treatment effect therefore needs to be understood alongside the response elicited by the task itself.

The paper’s broader resilience interpretation relied partly on preserved within-group recovery contrasts in the supplemented group and on heart-rate contrasts that were absent in the placebo group. However, the group-by-time-by-condition interaction was not significant for heart-rate variability, p=.125, or heart rate, p=.636. A significant change in one group and a nonsignificant change in another do not, by themselves, establish a significant difference between groups.

The endpoint samples were smaller than the completer population: heart-rate variability involved 33 and 35 participants, and cortisol 35 and 36. Recruitment and power calculations also constrain interpretation; the power calculation concerned vitamin D concentrations, not the precision of the stress outcome. Institutional collection rounds complicated exact awakening timing. Clinical characteristics and medications further limit transfer to healthy community populations.

The study supplies a useful independent human comparison with Rolf, but not a replication of the same protocol. Sex, clinical setting, dose, sampling and stress task differed. Neither trial demonstrated restored feedback, and the Hansen result should not be converted into a claim that vitamin D treats post-traumatic stress disorder or improves everyday psychological resilience.

A fatigue improvement does not identify its endocrine mechanism

Nowak and colleagues recruited otherwise healthy adults aged 20 to 50 who reported fatigue and had 25-hydroxyvitamin D below 20 ng/mL. The study excluded many alternative medical, psychiatric and sleep-related causes of fatigue, and restricted body mass index to 18 to 25. This creates a particularly selected population, unlike the multiple-sclerosis and forensic inpatient cohorts.

Participants received one supervised oral dose of 100,000 IU cholecalciferol or matching placebo and were followed for four weeks. This was a research protocol, not a supplement schedule for readers to copy. Of 122 participants who took the study medication, 120 entered the per-protocol analysis: 58 receiving vitamin D and 62 receiving placebo. One participant started venlafaxine and another was lost to follow-up.

The primary Fatigue Assessment Scale is a ten-item self-report instrument, with lower scores indicating less fatigue. Mean change was −3.3 points with vitamin D and −0.8 with placebo, a between-group difference of approximately 2.5 points, p=.01. An analysis including the participant who started venlafaxine retained the reported primary difference. The result is therefore more than an observation that supplemented participants improved over time: it includes a placebo comparison. Improvement on that scale occurred in 72% versus 50%, with an odds ratio of 2.63 (95% confidence interval 1.23 to 5.62). This is a different definition of improvement from the secondary measure below.

Nevertheless, another fatigue measure did not show a statistically significant difference. The investigators’ self-developed fatigue-course assessment recorded improvement in 48% versus 37%, p=.22. That instrument had not been validated, whereas the main scale had a stronger prior measurement basis, although the authors noted a language-validation limitation. The two results should be reported together rather than allowing either to erase the other.

Vitamin D status was measured by automated immunoassay. Its rise confirmed exposure, and PTH decreased while calcium and phosphate remained unchanged. Adverse-event reporting was similar between groups, with no serious events during this short follow-up; that does not establish safety of repeated large doses.

The trial measured neither cortisol nor HPA feedback. Its positive symptom result cannot establish that a stress-axis mechanism caused the improvement. The authors discussed possible mechanisms, but these were not measured mediators in the trial. Four weeks also provides no evidence of sustained benefit, occupational recovery or long-term safety of repeated dosing. The finding does not establish treatment for chronic fatigue syndrome or explain the null multiple-sclerosis fatigue result through an experimentally proven difference in mechanism.

T-cell experiments show one kind of glucocorticoid interaction

Xystrakis and colleagues investigated immune cells from people with glucocorticoid-resistant or glucocorticoid-sensitive asthma and healthy donors. The experimental ligand was active calcitriol, used with dexamethasone in cell cultures. It is important to distinguish this direct cellular exposure from oral nutritional vitamin D3, which was the intervention in the clinical trials.

Calcitriol combined with dexamethasone enhanced the generation of IL-10-secreting regulatory responses in this culture system. IL-10 is the immune-regulatory output at issue; it is not a measure of circulating cortisol. The study provides functional cellular evidence that the vitamin D and glucocorticoid responses can interact, rather than merely showing that a receptor is present.

The functional test was stronger than cytokine detection alone. Drug-conditioned cells inhibited responder-cell proliferation and allergen-driven Th2 cytokine production. Blocking the IL-10 receptor reversed suppression, whereas blocking TGF-beta did not. Flow cytometry, cytokine assays and transcript measurements supported an IL-10-secreting population with relatively low Foxp3, rather than establishing expansion of every regulatory-T-cell subtype.

In resistant-patient cultures, adding calcitriol brought IL-10 output towards the level seen in sensitive-patient cells given dexamethasone alone; it did not fully match sensitive-patient cells under all corresponding combined-treatment conditions. Overnight IL-10 pretreatment provided a further rescue. These comparator details limit the phrase “restored glucocorticoid responsiveness” to the response actually tested.

The receptor results require precise wording. Calcitriol did not itself increase glucocorticoid receptor expression. It prevented dexamethasone-associated receptor downregulation. IL-10 pretreatment, by contrast, increased receptor expression. Combining these observations into a statement that vitamin D simply increases glucocorticoid receptors would remove the experimental distinctions that make the mechanism interpretable.

The key resistant-patient comparisons included seven unique donors, although one donor was studied again a year later and contributed another culture experiment. Eight experiments are not eight independent patients. Culture concentrations were approximately 10⁻⁷ to 5×10⁻⁷ mol/L calcitriol, and the laboratory responses do not establish an equivalent exposure or effect after ordinary supplementation.

A small oral active-calcitriol pilot involved three resistant patients and four healthy participants receiving 0.5 micrograms daily for seven days, with subsequent cellular assessment. This was not a clinical asthma-efficacy trial. One displayed comparison used each participant’s maximum response at day three or seven, rather than a single common follow-up time. These features are important when judging how much human confirmation the pilot provides.

PBMC experiments show why the direction cannot be generalised

Kassi and colleagues studied peripheral blood mononuclear cells from 12 vitamin-D-deficient women aged 24 to 46. These mixed immune-cell preparations differ from the T-cell system used by Xystrakis. Cells were exposed to 1 or 10 nanomolar calcitriol for 11 days, with 100 nanomolar dexamethasone either added for the final two days or present concurrently throughout.

Calcitriol pretreatment attenuated dexamethasone-induced expression of GILZ, a glucocorticoid-responsive gene product, and reduced glucocorticoid receptor movement into the nucleus. Compared with dexamethasone alone, the reported GILZ reductions were 36.7% at 1 nanomolar and 60.6% at 10 nanomolar calcitriol (standard deviations 20.8 and 14 percentage points; both p<.05). The spread between donors was substantial, so these averages do not imply a uniform cellular response. Concurrent exposure did not reproduce the same GILZ result. Exposure sequence therefore mattered within the experiment itself. This is a particularly useful example for understanding Vitamin D Signalling Pathways: the order and duration of signals can affect the measured output.

The reported replication varied by assay: RNA measurements used 12 samples, protein measurements eight, and the confocal images represented at least six independent experiments. These numbers should not be treated as interchangeable. FKBP5 expression fell; this did not support increased FKBP5 as the explanation for reduced receptor movement into the nucleus. A separate histone-deacetylase inhibitor experiment contains disagreements between the methods and figure account about dose and sample size; it is not used here as a quantitative mechanistic anchor.

RT-PCR measured transcript changes, western blots assessed protein, and fractionation plus confocal imaging examined receptor location. Calcitriol reduced receptor abundance and increased Ser203 phosphorylation while reducing Ser211 phosphorylation. These associations suggested alternative mechanisms, without proving which change caused the GILZ response. Reduced NCoR1 expression likewise argued against increased co-repressor abundance as the explanation.

Kassi’s study received Unipharma funding, and the authors declared no conflicts of interest. That context accompanies the design limitations; it does not determine the result’s validity.

The two cellular papers do not provide equal and opposite estimates of one universal effect. They used different cell populations, exposure schedules and outcomes. One examined regulatory IL-10 responses in an asthma-related system; the other examined selected receptor-associated responses after prolonged pretreatment. Together they support context-dependent interaction while undermining an unqualified claim that vitamin D always increases glucocorticoid sensitivity.

Connecting the findings without inventing a completed pathway

The evidence supports three distinct statements. Particular cell systems show glucocorticoid interactions. The selected human trials did not establish cortisol or feedback restoration. A separate short fatigue trial found a benefit on its primary symptom scale in a deficient, otherwise healthy population without measuring the HPA mechanism. None of these statements needs to be suppressed to make the others intelligible.

From Glucocorticoid Responses in Cells to HPA Feedback explains the experimental steps missing between a peripheral receptor result and a central feedback claim. The broader coordination question in Vitamin D and Neuroendocrine Integration likewise requires evidence connecting central activity with peripheral outcomes. Vitamin D, Hypothalamic Signalling and Glucose Coordination: Full Study examines that distinction using targeted hypothalamic receptor and glucose experiments; those models cannot retrospectively supply an unmeasured mechanism for these human trials.

A reasonable future test would need a defined population, a meaningful baseline disturbance, suitable sampling or feedback measures and an analysis capable of comparing the intervention groups. Demonstrating mediation would additionally require evidence that the proposed intermediate change explains the outcome. This is an interpretation of the gaps in the cited designs, not a claim that such a complete pathway has already been verified.

Conclusion

Vitamin D: glucocorticoid interactions are experimentally demonstrable in selected peripheral cell systems, with direction and magnitude dependent on the model and exposure sequence. The selected clinical trials do not establish restored HPA feedback or a general stress-resilience benefit. The short-term fatigue result remains a bounded clinical finding with an unmeasured mechanism. Keeping these levels separate preserves the positive observations without turning them into a broader treatment claim.

Primary source and publication details

Hansen AL, Ambroziak G, Thornton D, Mundt JC, Kahn RE, Dahl L, Waage L, Kattenbraker D, Araujo P, Murison R, Rypdal K, Grung B. Vitamin D Supplementation during Winter: Effects on Stress Resilience in a Randomized Control Trial. Nutrients. 2020;12(11):E3258. DOI 10.3390/nu12113258. PMID 33114392.

Kassi E, Nasiri-Ansari N, Spilioti E, Kalotychou V, Apostolou PE, Moutsatsou P, Papavassiliou AG. Vitamin D interferes with glucocorticoid responsiveness in human peripheral blood mononuclear target cells. Cellular and molecular life sciences : CMLS. 2016;73(22):4341-4354. DOI 10.1007/s00018-016-2281-3. PMID 27220430.

Nowak A, Boesch L, Andres E, Battegay E, Hornemann T, Schmid C, Bischoff-Ferrari HA, Suter PM, Krayenbuehl PA. Effect of vitamin D3 on self-perceived fatigue: A double-blind randomized placebo-controlled trial. Medicine. 2016;95(52):e5353. DOI 10.1097/md.0000000000005353. PMID 28033244.

Rolf L, Damoiseaux J, Huitinga I, Kimenai D, van den Ouweland J, Hupperts R, Smolders J. Stress-Axis Regulation by Vitamin D3 in Multiple Sclerosis. Frontiers in neurology. 2018;9:263. DOI 10.3389/fneur.2018.00263. PMID 29755397.

Xystrakis E, Kusumakar S, Boswell S, Peek E, Urry Z, Richards DF, Adikibi T, Pridgeon C, Dallman M, Loke TK, Robinson DS, Barrat FJ, O’Garra A, Lavender P, Lee TH, Corrigan C, Hawrylowicz CM. Reversing the defective induction of IL-10-secreting regulatory T cells in glucocorticoid-resistant asthma patients. The Journal of clinical investigation. 2006;116(1):146-155. DOI 10.1172/jci21759. PMID 16341266.

Related reading

Physiology

Vitamin D and the HPA Axis

Explore how vitamin D interacts with the HPA axis and the body’s central stress-response system, including hormonal signalling, immune: endocrine coordination, circadian rhythm, and metabolic adaptation.

Read more →

Original sources

Source

Vitamin D Supplementation during Winter: Effects on Stress Resilience in a Randomized Control Trial

This study investigated the effects of vitamin D supplements during winter on biological markers of stress resilience such as psychophysiological activity, serotonin, and cortisol in a placebo-controlled, randomized clinical trial.

Publication details

Hansen AL, Ambroziak G, Thornton D, Mundt JC, Kahn RE, Dahl L, Waage L, Kattenbraker D, Araujo P, Murison R, Rypdal K, Grung B. Vitamin D Supplementation during Winter: Effects on Stress Resilience in a Randomized Control Trial. Nutrients. 2020;12(11):E3258. DOI 10.3390/nu12113258. PMID 33114392.

Read more →
Source

Vitamin D interferes with glucocorticoid responsiveness in human peripheral blood mononuclear target cells

Published in Cellular and molecular life sciences : CMLS (2016).

Publication details

Kassi E, Nasiri-Ansari N, Spilioti E, Kalotychou V, Apostolou PE, Moutsatsou P, Papavassiliou AG. Vitamin D interferes with glucocorticoid responsiveness in human peripheral blood mononuclear target cells. Cellular and molecular life sciences : CMLS. 2016;73(22):4341-4354. DOI 10.1007/s00018-016-2281-3. PMID 27220430.

Read more →
Source

Stress-Axis Regulation by Vitamin D3 in Multiple Sclerosis

Multiple sclerosis (MS) has been associated with both a poor vitamin D status and hyperactivity of the hypothalamus: pituitary: adrenal (HPA) axis.

Publication details

Rolf L, Damoiseaux J, Huitinga I, Kimenai D, van den Ouweland J, Hupperts R, Smolders J. Stress-Axis Regulation by Vitamin D3 in Multiple Sclerosis. Frontiers in neurology. 2018;9:263. DOI 10.3389/fneur.2018.00263. PMID 29755397.

Read more →
Source

Reversing the defective induction of IL-10-secreting regulatory T cells in glucocorticoid-resistant asthma patients

Published in The Journal of clinical investigation (2006).

Publication details

Xystrakis E, Kusumakar S, Boswell S, Peek E, Urry Z, Richards DF, Adikibi T, Pridgeon C, Dallman M, Loke TK, Robinson DS, Barrat FJ, O’Garra A, Lavender P, Lee TH, Corrigan C, Hawrylowicz CM. Reversing the defective induction of IL-10-secreting regulatory T cells in glucocorticoid-resistant asthma patients. The Journal of clinical investigation. 2006;116(1):146-155. DOI 10.1172/jci21759. PMID 16341266.

Read more →